Contributions
Abstract: EP1434
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Background: Mental comorbidities are considered as common among patients with multiple sclerosis (MS). They may have impact on care consumption, delay to diagnosis, disability progression, adherence to disease-modifying therapy but also on quality of life. International literature shows that the frequency of mental comorbidity in MS patients is higher than in general population. However, few data are available in France. In this context, the present study was performed to assess the frequency of patients affected by MS having mental comorbidity and more precisely mood disorders.
Method: MS Patients were identified between 2011 and 2015 in a random sample issued of French national health insurance system if they meet at least one out of the three following criteria: being under MS long disease duration status, being prescribed at least one disease-modifying therapy (DMT) specific for MS (dimethyl fumarate, beta interferon, fingolimod, glatiramer acetate, natalizumab or teriflunomide), having at least one hospital admission with a MS diagnosis. Mood disorders were considered as present if at least one reimbursement of a specific list of treatments was identified in 2015.
Results: A total of 1,153 patients with MS were alive in 2015. Most of them were declared as LDD status (N=1,009) from a median duration of 10 years, female to male sex-ratio was 2.5 and their median age was 50 years. At least one reimbursement for mood disorders treatment was observed for 349/1153 (30.3%) of patients. Of them, 187 received only a treatment specific to depression and 25 only a treatment specific to bipolar disorders. Patients with mood disorders were older than patients without mood disorders (median age: 54 vs 49, respectively) and their number of general practitioner visits was higher (median at 7 visits per year vs 5).
Conclusion: This study performed on sample of national healthcare databases available in France shows that about one third of patients affected by MS had a prescription for treatment of mood disorders over 1 year period. The next objectives are to extent this analysis on a healthy control group from the French general population in order to compare the frequencies of mental comorbidities but also with control group from the population of people diagnosed with rheumatoid arthritis to estimate the burden of MS on mental health compared to another chronic disease.
Disclosure: This work was supported by the ARSEP foundation
Alice Guilleux has no disclosure to report.
Jonathan Roux has no disclosure to report.
Emmanuelle Leray reports personal fees as speaker or consultant from Novartis and Sanofi Genzyme, outside the submitted work, and travel grants from Novartis and Roche SAS. Sources of funding in the last year came from the French ARSEP Foundation, the French National Security Agency for Medicines and Health Products, the EDMUS Foundation, and donation from Roche SAS.
Abstract: EP1434
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Background: Mental comorbidities are considered as common among patients with multiple sclerosis (MS). They may have impact on care consumption, delay to diagnosis, disability progression, adherence to disease-modifying therapy but also on quality of life. International literature shows that the frequency of mental comorbidity in MS patients is higher than in general population. However, few data are available in France. In this context, the present study was performed to assess the frequency of patients affected by MS having mental comorbidity and more precisely mood disorders.
Method: MS Patients were identified between 2011 and 2015 in a random sample issued of French national health insurance system if they meet at least one out of the three following criteria: being under MS long disease duration status, being prescribed at least one disease-modifying therapy (DMT) specific for MS (dimethyl fumarate, beta interferon, fingolimod, glatiramer acetate, natalizumab or teriflunomide), having at least one hospital admission with a MS diagnosis. Mood disorders were considered as present if at least one reimbursement of a specific list of treatments was identified in 2015.
Results: A total of 1,153 patients with MS were alive in 2015. Most of them were declared as LDD status (N=1,009) from a median duration of 10 years, female to male sex-ratio was 2.5 and their median age was 50 years. At least one reimbursement for mood disorders treatment was observed for 349/1153 (30.3%) of patients. Of them, 187 received only a treatment specific to depression and 25 only a treatment specific to bipolar disorders. Patients with mood disorders were older than patients without mood disorders (median age: 54 vs 49, respectively) and their number of general practitioner visits was higher (median at 7 visits per year vs 5).
Conclusion: This study performed on sample of national healthcare databases available in France shows that about one third of patients affected by MS had a prescription for treatment of mood disorders over 1 year period. The next objectives are to extent this analysis on a healthy control group from the French general population in order to compare the frequencies of mental comorbidities but also with control group from the population of people diagnosed with rheumatoid arthritis to estimate the burden of MS on mental health compared to another chronic disease.
Disclosure: This work was supported by the ARSEP foundation
Alice Guilleux has no disclosure to report.
Jonathan Roux has no disclosure to report.
Emmanuelle Leray reports personal fees as speaker or consultant from Novartis and Sanofi Genzyme, outside the submitted work, and travel grants from Novartis and Roche SAS. Sources of funding in the last year came from the French ARSEP Foundation, the French National Security Agency for Medicines and Health Products, the EDMUS Foundation, and donation from Roche SAS.